hong kong

Alibaba’s successful HK listing, combined with mounting pressure from PE investors, is forcing Chinese companies to consider listing in 2020 despite the woeful stock market performance of many who floated in 2019.

Virtual banks have come on in leaps and bounds this year, but traditional banks believe that investment in technology and a personal touch will see off the newcomers.

We are setting out the rationale for the choices made in the Deal Awards for the Achievement Awards for 2019.

Alibaba came back to Asia in November and dominated the equity landscape. But people are now starting to ask what markets next year are going to look like.

Central bankers from China, Hong Kong and Thailand plan to issue their own digital currencies, spurred by the threat to their monetary policy. They were previously too complacent, says the IMF.

Thanks to IPOs from ESR and Lotte REIT, real estate was the sector to watch in October, according to data from Dealogic.

SinoMab pushes forward with what could be the fourth-largest biotech listing in Hong Kong this year as investors' appetite for the sector picks up.

Taiwan wants to lure wealthy investors' capital from Singapore and above all Hong Kong but it ideally needs lower tax rates to do so, says a senior local regulator.

Even if Hong Kong's social landscape remains fractured, biotech firms continue to be lured to the HKEX, with Ascentage Pharma the latest to float.